Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 12

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 12
---
 vitro diagnostic (IVD) test that is designed, manufactured, and performed within a single laboratory. The development of the lab-developed test includes custom assay design and validation of the test system, including accuracy and replicability of the test. |
| ● | “Lead Projects” refers to ALS-4 and SACT-1.                                                                                                                                                                                                                                                                           |

<div align='center'>v</div>

| ● | “Libra” refers to Libra Sciences Limited, a VIE in which we hold 97.27% economic interest and 31.51% voting power. Libra is incorporated under the laws of the Cayman Islands. We are not deemed as the primary beneficiary of Libra for accounting purposes. |
| ● | “LIMS” refers to Laboratory Information Management System.                                                                                                                                                                                                    |
| ● | “Major Patent Jurisdictions” refers to the United States, member states of the European Patent Organization and the People’s Republic of China.                                                                                                               |

| ● | “MCI” refers to Mild Cognitive Impairment. |

| ● | “microRNA” (miRNA) refers to non-coding small nucleic acid molecules. |

| ● | “Nativus” refers to Nativus Life Sciences Limited, a wholly-owned subsidiary of Aptorum Group.                                                                                                                                         |
| ● | “NMPA” refers to China’s National Medical Products Administration and its predecessor, the China Food and Drug Administration.                                                                                                         |
| ● | “ND” refers to neurodegenerative diseases.                                                                                                                                                                                             |
| ● | “NDA” refers to a New Drug Application issued by the FDA.                                                                                                                                                                              |
| ● | “NIH” refers to National Institute of Health.                                                                                                                                                                                          |
| ● | “Ordinary Shares” refers to the Class A Ordinary Shares and Class B Ordinary Shares collectively.                                                                                                                                      |
| ● | “PD” refers to Parkinson’s disease.                                                                                                                                                                                                    |
| ● | “PRC” and “China” refer to the People’s Republic of China.                                                                                                                                                                             |
| ● | “Restructure” refers to the Company’s change from an investment fund with management shares and non-voting participating redeemable preference shares to a holding company with operating subsidiaries, effective as of March 1, 2017. |
| ● | “R&D” refers to research and development.                                                                                                                                                                                              |
| ● | “R&D Center” refers to an in-house pharmaceutical development center located in Hong Kong Science and Technology Park.                                                                                                                 |

<div align='center'>